Company profile: ImmunoMet Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical oncology products for cancer patients, including Lixumistat (IM156), an orally bioavailable small molecule inhibitor of Protein Complex 1 that targets Oxidative Phosphorylation to reduce aberrant cell growth in cancer and fibrosis.
Products and services
- Oncology Product Development: Engineers biopharmaceutical-grade oncology products for cancer patients, developing oncology therapeutics for cancer care with focused product development activities
- Oncology Product Commercialization: Delivers commercial-scale commercialization of oncology products for cancer patients, executing commercialization activities for oncology therapeutics intended for cancer care
- Lixumistat (IM156): Produces a small-molecule, orally bioavailable inhibitor of Protein Complex 1, targeting Oxidative Phosphorylation to reduce aberrant cell growth in cancer and fibrosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ImmunoMet Therapeutics
Cirrus Bio
HQ: United States
Website
- Description: Provider of solutions for common health issues that impact well-being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cirrus Bio company profile →
Lumicell
HQ: United States
Website
- Description: Provider of image-guided cancer surgery solutions, including the Lumicell Direct Visualization System (DVS), a fluorescence-guided imaging system that detects residual cancerous tissue in real time during lumpectomy, and LUMISIGHT (pegulicianine), an optical imaging agent used with DVS to highlight cancerous tissue during lumpectomy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumicell company profile →
Ceptaris
HQ: United States
Website
- Description: Provider of a proprietary gel formulation of mechlorethamine hydrochloride under development for the treatment of early-stage (stages I–IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL); if approved, it would be the first topical treatment for this indication.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ceptaris company profile →
Artiva Bio
HQ: United States
Website
- Description: Provider of allogeneic NK cell therapies and an umbilical cord blood–based manufacturing platform for off-the-shelf use. Products include AlloNK, a non-genetically modified NK therapy enhancing monoclonal antibody or NK engager activity in trials for autoimmune diseases and cancers; AB-201, a clinical-stage HER2-targeted CAR-NK for solid tumors; and AB-205, a preclinical CAR-NK for CD5+ T-cell lymphomas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artiva Bio company profile →
F-star
HQ: United Kingdom
Website
- Description: Provider of novel bispecific antibody therapeutics focused on immuno-oncology and oncology, developing bispecific antibody products to improve the standard of care, with the ability to create and develop Fcab™ antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F-star company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ImmunoMet Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ImmunoMet Therapeutics
2.2 - Growth funds investing in similar companies to ImmunoMet Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ImmunoMet Therapeutics
4.2 - Public trading comparable groups for ImmunoMet Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →